- source： CentryMed
- author： CentryMed
-
2025.07.23
CMDE005 is a recombinant human anti-EGFR-CD3 enzyme-controlled bispecific antibody for injection developed using CentryMed’s proprietary proBiTE platform. The drug offers advantages including:
High expression yield during production
High stability
Long half-life
Clinically, CMDE005 is expected to significantly improve drug safety and efficacy, reduce market costs, and address unmet medical needs. To date, no enzyme-controlled bispecific antibody product has been approved globally.
Recent reports indicate that two U.S.-based innovative biopharmaceutical companies, Janux and CytomX, have similar "enzyme-controlled" candidates in Phase I clinical development. These candidates have shown preliminary significant tumor control rates and favorable safety in advanced non-small cell lung cancer and pancreatic cancer, respectively, attracting widespread attention and anticipation in the global innovative drug field.
We believe the successful development of CMDE005—a convenient-to-use (direct intravenous infusion), broad-spectrum (distinct from individualized BAT therapies) EGFR×CD3 enzyme-controlled bispecific antibody—will provide additional therapeutic options and clinical benefits to a broad population of cancer patients.